1Marth E ,Klein HB. Albumin is a necessary stabiliser of TBE vaccine to avoid fever in children after vaccination [J]. Vaccine,2001,20 (3-4): 532-537.
2Pavlova MA, Bektimirov LI,Ladyzhenskaia IP,et al. Comparative study of inactivated cultured vaccines against tick-borne encephalitis manufactured in Russia and in Austria by the 'Immuno' firm[J]. Vopr Virusol, 1996,41: 221-224.
3Pletnev AG,Men R. Attenuation of the Langat tick-borne flavivirus by chimerisation with mosquito-borne flavivirus dengue type 4[J]. Proc Natl Acad Sci USA, 1998,95(4):1746-1751.
4Mandl CW,Ecker M,Holzmann H,et al. Infectious cDNA clones of tick-borne encephalitis virus European subtype prototypic strain Neudoerfl and high virulence strain Hypr[J]. J Gen Virol, 1997,78 (Pt 5): 1049-1057.
5Mandl CW,Holzmann H,Meixner T,et al.Spontaneous and engineered deletions in the 3′ noncoding region of tick-borne encephalitis virus :construction of highly attenuated mutants of a flavivirus[J]. J Virol,1998,72 (3): 2132-2140.
6Kofler RM,Leitner A,O' Riordain G,et al.Spontaneous mutations restore the viability of tick-borne encephalitis virus mutants with largedeletionsinproteinC[J]. J Virol, 2003,77(1 ) :443-451.
7Kofler RM,Heinz FX,Mandl CW. Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence [J]. J Virol, 2002,76(7): 3534-3543.
8Allison SL,Schalich J,Stiasny K,et al.Mutational evidence for an internal fusion peptide in flavivirus envelope protein E [J].J Virol, 2001,75 ( 9 ): 4268-4275.
9Pletnev AG, Bray M, Huggins J, et al.Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses [J]. Proc Natl Acad Sci USA, 1992,89(21 ):10532-10536.
10Pletnev AG,Bray M,Lai CJ,et al. Chimeric tick-borne encephalitis and dengue type 4 viruses:effects of mutations on neurovirulence in mice[J]. J Virol, 1993,67(8):4956-4963.
